diagnost anim health
distribut product servic
veterinari water test dairi market
leader pet healthcar innov
rang diagnost
revenu
requir disclosur end report
up pt
heska corpor neogen corpor particip
annual cl king best idea confer thursday septemb
new york citi see list compani confirm regist click
anoth great survey anim health
suggest anim health ah macro could actual acceler
increas price target compani
specif obtain above-market growth launch sdma
catalyst anticip launch fecal antigen
product survey well thesi three driver growth
new product refer lab market share gain robust growth outsid
unit state lead above-guid long-term revenu growth
signific oper margin expans reiter buy rate
idexx anim health found best macro data record
vet told us expect patient
volum growth next year exceed vs averag around
vet also report econom euthanasia
complianc could increas meaning net-net
posit survey macro-wis uniqu stand benefit
strong macro
fecal antigen superior survey found vet
agre strongli agre fecal antigen test superior
visual test done microscop vet strongli
disagre fecal antigen test vet ambival
ambival view suggest test see much
sdma penetr found chemistri user
alreadi adopt sdma one use said
use regularli dont yet know regularli
mean prior survey found veterinarian said averag
would put chemistri panel
limit competit threat although zoeti
henri schein nr strateg decis creat new power
center diagnost software/servic respect see
limit direct impact idexx core revenue-gener
busi fact vet said zoeti bundl
abaxi abaxa would make practic like buy
abaxi diagnost product vet said
buy
henri schein
quarter report result august
open expect good quarter refer lab consum
given strong macro pm data lab volum alway
correl quarter quarter good macro could effect
guidanc think hold stock print good idea
although downsid print idexx reput
addit thought analyst day idexx analyst
day approach mid-august wouldnt surpris
compani announc product late call
keep mind like analyst day long-term strategi
focus doesnt typic announc new product event
model assum fecal antigen drive revenu
product launch would increment product launch timelin
revis price target base price-to-earnings multipl vs
previous estim higher multipl reflect higher
growth increas competitor multipl pass second
quarter bring us closer note neoga abaxi
hskaa averag trade calendar consensu ep
estim feel comfort trade premium
anim health
risk achiev price target
risk includ currenc geopolit environ relianc distributor
regul multipl sole supplier vet industri macro situat price
concess competit
view current cl king meet event calendar coverag univers
page
